Endometrial Cancer

However, CD68-based assessment alone showed no significant association with clinicopathological parameters in our study. Hence, further studies with a larger sample size and additional markers are recommended.

In summary, high glucose may promote the progression of PR-negative EC by downregulating CD146 expression and inducing EMT, suggesting that CD146 represents a promising therapeutic target for precision treatment strategies in EC, particularly in patients with concurrent glucose metabolism dysregulation.

Furthermore, we propose translational strategies for precision application: LKB1/PTEN status-based patient stratification, innovative combinations with CDK4/6 inhibitors, mTOR inhibitors, and immune checkpoint inhibitors, and clinical pathway optimization. By bridging metabolic endocrinology and gynecologic oncology, the available data provide preliminary theoretical basis to explore future shift of metformin from empirical off-label reuse toward biomarker-guided individualized medication, which still needs large-scale prospective validation.

P=N/A, N=30, Not yet recruiting, Royal Marsden NHS Foundation Trust

P=N/A, N=5000, Recruiting, Dana-Farber Cancer Institute

Our study supports the prognostic relevance of both sentinel lymph node assessment and molecular classification in early-stage endometrial cancer, with potential implications for post-operative risk stratification and management.

Nevertheless, clinical translation remains challenged by response heterogeneity attributable to tumor heterogeneity, the emergence of resistance mechanisms, and class-specific adverse events including ocular toxicity, interstitial lung disease (ILD), hepatotoxicity, and peripheral neuropathy. Continued refinement of next-generation ADC platforms - encompassing bispecific ADCs, dual-payload ADCs, peptide-drug conjugates (PDCs), and radionuclide-conjugated drugs - is anticipated to overcome current limitations and deliver superior oncologic outcomes.

These findings highlight important molecular features of EC in Kurdish patients and may support future development of targeted therapeutic strategies. Further validation with larger cohorts is recommended.

Furthermore, the combination of Rituximab and Pembrolizumab resulted in enhanced and more potent suppression of cancer cell growth than either monotherapy alone. In conclusion, the combination of anti-CD20 antibody and PD-1 antibody exerts synergistic antiproliferative effects on EC cells in vitro.

The best cutoff point of ADC to discrimination was 695, yielding a sensitivity of 100% and specificity of 83%. In patients with EC, assessing tumor ADC values on MRI can serve as a valuable tool for predicting p53abn subtype.

This case illustrates the breadth of fibrotic disease that can occur in individuals with Myhre syndrome by describing the first reported case of pleural remodeling leading to fibrothorax. Additionally, our patient's diagnosis of endometrial cancer strengthens the evidence for the proposed increased risk of malignancy in Myhre syndrome.

Six months later, she died and was found at autopsy to have metastatic endometrial cancer. We hypothesized that the positivity for anti-GBM antibodies and MPO-ANCA and the malignant tumor may have been related.